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Abstract
Background: Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. Combination therapy
with three antiplatelet agents might maximise the benefit of antiplatelet treatment in the secondary prevention of
ischaemic stroke.
Methodology/Principal Findings: A randomised, parallel group, observer-blinded phase II trial compared the combination
of aspirin, clopidogrel and dipyridamole with aspirin alone. Adult patients with ischaemic stroke or transient ischaemic
attack (TIA) within 5 years were included. The primary outcome was tolerability to treatment assessed as the number of
patients completing randomised treatment. Recruitment was halted prematurely after publication of the ESPRIT trial (which
confirmed that combined aspirin and dipyridamole is more effective than aspirin alone). 17 patients were enrolled: male 12
(71%), mean age 62 (SD 13) years, lacunar stroke syndrome 12 (71%), median stroke/TIA onset to randomisation 8 months.
Treatment was discontinued in 4 of 9 (44%) patients receiving triple therapy vs. none of 8 taking aspirin (p = 0.08). One
recurrent stroke occurred in a patient in the triple group who was noncompliant of all antiplatelet medications. The number
of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple
therapy group (p,0.01).
Conclusions/Significance: Long term triple antiplatelet therapy was asociated with a significant increase in adverse events
and bleeding rates, and their severity, and a trend to increased discontinuations. However, the patients had a low risk of
recurrence and future trials should focus on short term therapy in high risk patients characterised by a very recent event or
failure of dual antiplatelet therapy.
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Introduction
Increased platelet activity plays a critical role in the pathophys-
iology of non cardioembolic ischaemic stroke, both in its initial
cause and the subsequent risk of recurrence. Several antiplatelet
agents have been used to prevent recurrence, [1] these having
different mechanisms for inhibiting platelets. The archetypal
agent, aspirin (A), irreversibly inhibits cyclo-oxygenase and
reduced the relative risk of stroke recurrence by 15–20% across
a wide range of trials.[2] Clopidogrel (C, a pro-drug which
antagonises ADP receptors), showed a slight benefit over aspirin in
a mixed population of patients with vascular disease;[3] no
difference was seen in the sub-group of patients with prior
ischaemic stroke.[3] Dipyridamole (D), an inhibitor of phospho-
diesterase and adenosine uptake by platelets, had comparable
efficacy to aspirin in one trial.[4] Dual therapy with the
combination of aspirin and dipyridamole was superior to aspirin
alone in preventing stroke recurrence [4,5] and had twice the
efficacy of mono-therapy when compared with placebo.[4,6]
Although the combination of aspirin and clopidogrel was superior
to aspirin alone in preventing vascular events in cardiac patients
with unstable angina or requiring percutaneous coronary
intervention, [7,8] it showed no overall benefit in patients with
stable vascular disease or at risk of developing a first vascular
event.[9] However, two small trials involving patients at high risk
of stroke recurrence suggested that combined aspirin and
clopidogrel were superior to aspirin alone.[10,11]
If two antiplatelet agents are superior to one then three agents
with differing modes of action might be better still, providing the
risk of bleeding does not become excessive. In laboratory studies,
we found that the combination of aspirin, dipyridamole and AR-
C69931 (a direct-acting antagonist of the ADP receptor) was
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superior to dual or mono-therapy in inhibiting platelet aggregation
and activation, leukocyte activation, and the formation of platelet
leucocyte conjugates in vitro.[12] However, in normal subjects and
patients with prior ischaemic stroke, short-term triple therapy was
no more effective than combined aspirin and clopidogrel in
moderating leucocyte and platelet function.[13] In addition to
antiplatelet effects, these agents have non-platelet effects on
thrombosis, inflammation and endothelial function which may
also play a part in stroke prevention; for example, dipyridamole
reduces circulating von Willebrand factor levels and blood
pressure [14,15] whilst clopidogrel may release prostacyclin and
tissue plasminogen activator.[16]
We have previously described the use of open-label triple
antiplatelet therapy in patients who have suffered stroke
recurrence while taking dual therapy.[17] Here, we report a
phase II trial which assessed the safety, tolerability and feasibility
of giving triple antiplatelet therapy in comparison with aspirin (the
UK standard of care at the time the trial commenced) alone in
patients with prior ischaemic cerebrovascular disease.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Adult patients with ischaemic stroke or transient ischaemic
attack (TIA) within the past 5 years were identified and enrolled
from Nottingham City Hospital (NCH). Principal exclusion
criteria included a history of peptic ulcer disease; prior cerebral
haemorrhage; anaemia; thrombocytopaenia; hypersensitivity or
intolerance to any of the antiplatelet agents; need for dual
antiplatelet therapy, anticoagulation or non-steroidal anti-inflam-
matory drugs; or involvement in another clinical trial. Full written
informed consent was obtained from all patients prior to
randomisation. Patients who had not previously received dipyri-
damole were given open label modified release dipyridamole
200 mg (with aspirin) for a period of 2 weeks; only those patients
without significant adverse events continued to randomisation
which was performed following a three week washout period when
only aspirin was taken.
Ethics
The study was approved by the Nottingham Local Research
Ethics Committee (October 2001), had a ‘Medicines and Healthcare
products Regulatory Agency’ Clinical Trial Authorisation (August
2001) and International Trial Number (ISRCTN83673558), and
was performed according to the Declaration of Helsinki and the
International Conference on Harmonisation of Good Clinical
Practice guidelines. All patients gave written informed consent; if
the patient was not competent to give assent (e.g. dysphasia,
confusion) a relative was approached to give assent.
Interventions
Patients were randomised to receive either open-label combined
aspirin (A, 75 mg od), clopidogrel (C, 75 mg od), and modified
release dipyridamole (D, 200 mg bd) (ACD) or aspirin (75 mg od)
alone (no dipyridamole or clopidogrel placebo) on a 1:1 ratio.
Mono-therapy with aspirin was chosen as the active comparator
since this was the standard of care at the time of trial design; the
comparison of triple with mono therapy meant that a smaller
sample size was possible since any difference in the primary
outcome (tolerability) was likely to be maximised.
Objectives
The trial comprised a prospective, randomised, single-centre,
observer-blinded, aspirin-controlled phase II trial of triple
antiplatelet therapy in patients with previous ischaemic stroke or
transient ischaemic attack. The aim was to test the safety,
tolerability and feasibility of combined aspirin, clopidogrel and
dipyridamole; additional haematological and haemodynamic
measures were also made.
Outcomes
The primary outcome was tolerability of treatment assessed as
the number of patients completing randomised treatment at final
follow up. Secondary outcomes included safety (mortality), serious
adverse events (SAEs), stroke recurrence (ischaemic or haemor-
rhagic), and extra-cranial bleeding (major and/or minor).
Haematology measures were performed at baseline and 2 weeks
after starting treatment using our previously published methodol-
ogy.[13] Venepuncture was performed after 10 minutes of rest and
blood collected into hirudin. Platelet aggregation was performed in
whole blood using aliquots stirred with ADP (final concentration
3 mmol/L), collagen (2 mg/mL) or platelet activating factor (PAF,
1 mmol/L). Aggregation was assessed at 4 minutes by counting the
number of fixed single platelets relative to the starting platelet
count using an Ultra-Flo 100 Whole Blood Platelet Counter.[13]
Platelet-leucocyte conjugate formation and leucocyte CD11b
expression (a measure of leucocyte activation) in response to ADP,
collagen or PAF were determined by flow cytometry. 100 ml aliquots
of the blood were treated with Erythrolyse solution for 10 min at
room temperature, centrifuged and then washed.[13] 30 ml aliquots
were incubated with saturating concentrations of anti-CD14:PE to
identify monocytes and anti-CD42a:FITC to identify platelets bound
to monocytes and/or neutrophils. Platelet-monocyte and platelet-
neutrophil conjugates were then quantified by flow cytometry.
Further 30 ml aliquots were incubated with anti-CD14:PE and anti-
CD11b:FITC to detect leucocyte activation.[13]
Platelet-leucocyte conjugates and leucocyte CD11b expression
were quantified using a FACScan flow cytometer (Becton Dickinson)
equipped with a 5 W laser operating at 15 mW power and a
wavelength of 488 nm, and connected to an Apple Mac comput-
er.[13] Leucocytes were monitored using forward and side light
scatter, and fluorescence. Monocytes were differentiated from other
leucocytes by their CD14:PE positivity. Platelet-leucocyte conjugates
are reported as the median CD42a fluorescence of the leucocyte
populations. CD11b expression is reported as the median
CD11b:FITC fluorescence of the leucocyte populations.[13]
Full blood count measures for haemoglobin, and red cell,
platelet and white cell count were performed at baseline and final
follow-up by Nottingham City Hospital’s clinical haematology
laboratory.
Since dipyridamole has vasoactive properties, peripheral blood
pressure (systolic BP, diastolic BP, postural drop) and heart rate
were measured with a validated digital readout oscillometric
device (Omron HEM-705CP, Illinois, US) at baseline, 2 weeks, 3
months and final follow up, with measurements performed blinded
to treatment assignment.
Sample size
A sample size of 51 was required assuming the number of subjects
completing treatment to the end of the trial was 55% in the ACD
group and 90% with aspirin alone, with significance 0.05, power (1-
beta) 0.80, and 1:1 randomisation (ACD:A). The assumptions were
based on previous experience with triple antiplatlet therapy and, in
particular, the propensity for research subjects to develop headache
with dipyridamole. No interim analysis was planned.
Triple Therapy for Stroke
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Randomization—Sequence generation
Randomisation was performed following consent using com-
puter minimisation on age (.70 years), delay from ischaemic
event, ischaemic event (stroke or TIA) and baseline systolic blood
pressure (SBP). This approach ensures concealment of allocation
and adds to statistical power.[18]
Randomization—Allocation concealment
Assignment was changed randomly for 10% of patients to
prevent researchers from trying to guess the next allocation.
Randomization—Implementation
Patients were identified and enrolled by research nurses (with
consent obtained by clinical research fellows); treatment assign-
ment was performed by a third party.
Blinding
The interventions were unblinded to both patients and treating
staff. However, patient assessments on and at the end of treatment,
adjudication of events, and assessment of haematology and
haemodynamic measures, were performed blinded to treatment
assignment by trained staff.
Statistical methods
Data are presented as mean (standard deviation, SD), median
(interquartile range, IQR) or number (%). Data were compared
using Fisher’s Exact test, repeated measures ANOVA, or
ANCOVA with adjustment for baseline values. Adverse events
were re-coded as ordinal variables, with data scored as follows: no
bleed = 0, minor bleed= 1, major bleed = 2 and no adverse
event = 0, adverse event = 1, non fatal serious adverse event = 2,
death = 3. These ordinal scores were then analysed by treatment
group using a Mann-Whitney U test.[19] Analyses were
performed using SAS (version 8) and were by intention-to-treat;
statistical significance was taken at p,0.05. No adjustments for
multiple comparisons were made.
Results
Participant flow and recruitment
Seventeen patients were enrolled between 2002 and 2006
(figure 1). The trial was stopped prematurely following publication
of the ESPRIT trial which confirmed ESPS II in showing that
combined aspirin and dipyridamole is superior to aspirin alone in
preventing recurrent stroke and other vascular events.[4,5]
Additionally, the UK National Institute of Clinical Excellence
recommend this combination as first line therapy for patients with
prior ischaemic cerebrovascular disease.[20] As such, we consid-
ered it unethical to continue randomising patients to receive
mono-therapy with aspirin.
Baseline data and numbers analysed
9 patients were randomised to triple therapy and 8 to aspirin.
Both groups were matched for age, baseline event (stroke or TIA)
and stroke syndrome (table 1). Patients were enrolled at an average
of 12 months (range 1.5–30) after their stroke or TIA. The total
exposure time to treatment was 282 months (triple 138, aspirin
144 months).
Outcomes and estimation
Treatment discontinuations numbered 4 (44%) in the triple
therapy group: bruising 1 patient, gastrointestinal bleeding 2, and
Figure 1. Flow of patients through trial.
doi:10.1371/journal.pone.0002852.g001
Table 1. Baseline characteristics of patients. Number (%),
mean (standard deviation), or median [interquartile range].
Aspirin Triple
Number 8 9
Sex, male (%) 6 (75) 6 (67)
Age (years) 61 (14) 63 (12)
Time to randomisation (months) 10 [18] 8 [5]
Randomisation event (%)
Stroke 7 (88) 8 (89)
Transient ischaemic attack 1 (13) 1 (11)
Lacunar syndrome (%) 5 (63) 7 (78)
Location, left hemisphere (%) 4 (50) 3 (33)
Previous family history of stroke (%) 3 (38) 4 (44)
Previous stroke or TIA (%) 1 (13) 1 (11)
Hypertension (%) 5 (63) 6 (67)
Diabetes (%) 1 (13) 1 (11)
Hyperlipidaemia (%) 6 (75) 4 (44)
Atrial fibrillation (%) 0 (0) 0 (0)
Ischaemic heart disease (%) 1 (13) 0 (0)
Peripheral vascular disease (%) 1 (13) 1 (11)
Current smoker (%) 3 (38) 6 (67)
Systolic blood pressure (mmHg) 132 (20) 148 (21)
Diastolic blood pressure (mmHg) 78 (12) 83 (9)
Postural blood pressure drop (mmHg) 6 (18) 27 (14)
Heart rate (bpm) 70 (8) 76 (11)
doi:10.1371/journal.pone.0002852.t001
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non-compliance to all trial drugs 1; no patients stopped mono-
therapy (aspirin alone) early (p = 0.08) (table 2)
Ancillary analyses
In comparison with aspirin, triple therapy appeared to exhibit
enhanced antiplatelet effects manifest as reduced collagen-induced
platelet aggregation and monocyte activation, and ADP-induced
platelet-monocyte conjugation (table 3). Haemoglobin levels at
final follow up did not differ between the triple therapy and aspirin
groups (13.4 vs. 13.9 g/dL, p = 0.76).
No significant difference in systolic and diastolic blood pressure,
postural drop in blood pressure, or heart rate were present
between triple therapy and aspirin. There was a non-significant
trend to a reduced rate pressure product over time in the triple
therapy group (table 4).
Adverse events
One patient died in the triple therapy group of acute myeloid
leukaemia; no patients died in the aspirin group. When bleeding
events were analysed as ordinal data (no bleed, minor bleed, major
bleed)[19], significantly increased rates were seen in the triple
therapy group (p,0.01). Similarly, there was a significant increase
in the number and severity of adverse events (ordered as no event,
adverse event, non-fatal serious adverse event, death) in the triple
group (p,0.01) (table 2 and figure 2). Only one of the SAEs was
thought to be related to treatment. There was a non-significant
difference in efficacy between treatment groups (p = 0.53); one
recurrent stroke (non-disabling) occurred in a patient randomised
to triple therapy who was noncompliant of all three antiplatelet
agents.
Discussion
Interpretation
This phase II trial has found that treatment with triple
antiplatelet therapy was associated with a trend to increased
treatment drop-outs as compared with aspirin alone (treatment
discontinuation 44% in the triple group versus 0% in the aspirin
group) in patients at low risk of stroke recurrence. 3 of the 4
patients who ceased therapy prematurely did so with symptoms
related to bleeding or bruising; 1 of these events was defined as
serious. However, long term aspirin monotherapy may be safer
with less (and less severe) bleeding and fewer (and less severe)
adverse events than long term triple antiplatelet therapy. The
finding of an increase in bleeding with triple therapy is supported
by laboratory testing ex vivo where reduced platelet aggregation (as
well as reduced monocyte activation and the formation of platelet-
Table 2. Adverse Events by treatment assignment and patient.
Treatment Trial no.
Timing
(months)
Serious Adverse
Event
Relationship of
event to treatment
Triple 1 Diuretic-induced hyponatraemia/collapse 9 SAE Not related
Gastritis (no gastroscopy) with anaemia{ 9 Probable
4 Shortness of breath 0.5 Unlikely
6 Bruising 3 Probable
10 Upper gastrointestinal bleed{ 6 SAE Probable
Acute myeloid leukaemia (when off treatment) 15 SAE (fatal) Not related
11 Prolonged bleeding at a skin cut 0.5 Probable
Retinal vein occlusion 15 Unlikely
12 Recurrent minor stroke of unknown type (when non-
compliant with all medications{)
12 Possible
14 Bruising 3 Probable
17 Bruising following minor trauma 0.5 Possible
Headache 3 Probable
Bruising{ 3 Probable
Aspirin 13 Tired 0.5 Unlikely
15 Diarrhoea, stomach cramps 2 Possible
{Leading to treatment cessation.
SAE: serious adverse event.
doi:10.1371/journal.pone.0002852.t002
Table 3. Haematological measures at week 2; mean
(standard deviation); comparison by ANCOVA with
adjustment for baseline values.
Agonist Aspirin Triple
ANCOVA
p value
Aggregation (at 4 mins) ADP 42.6 (17.9) 34.1 (24.4) 0.38
Collagen 84.0 (5.5) 69.9 (11.1) 0.05
PAF 26.2 (13.4) 42.1 (21.9) 0.89
Monocyte activation
(CD11b)
ADP 89.2 (10.8) 80.4 (12.6) 0.17
Collagen 165.0 (107.8) 95.7 (45.5) 0.02
PAF 159.8 (110.6) 144.0 (57.7) 0.20
Platelet-monocyte
conjugates
ADP 117.8 (76.6) 74.1 (34.4) 0.04
Collagen 97.4 (3.8) 97.1 (1.9) 0.23
PAF 90.8 (6.4) 93.0 (7.0) 0.23
doi:10.1371/journal.pone.0002852.t003
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monocyte conjugates) was seen with triple therapy as compared
with aspirin. Our previous work in vitro suggests that the measured
antiplatelet effects will largely have been due to the combination of
aspirin and clopidogrel rather than dipyridamole.[13] Further-
more, increased bleeding has been seen in trials of combined
aspirin and clopidogrel [7–9] but not combined aspirin and
dipyridamole.[4,5]
Dipyridamole has vasoactive properties due to its effect as an
inhibitor of phosphodiesterase and red cell adenosine uptake. As
such, it lowers blood pressure, particularly when given intrave-
nously [21] but only modestly when given orally.[14] Although no
hypotensive effects were seen in this study, a trend to a reduced
rate pressure product was apparent in patients randomised to
triple therapy as compared with aspirin alone. Since aspirin and
clopidogrel do not have vasoactive properties, it is most like that
dipyridamole contributed to any vasoactive effects seen here.
The major limitation of this study is its unintended small size
resulting from having to stop recruitment early. Recruitment was
halted prematurely with only 17 of the planned 51 patients
recruited following the publication of ESPRIT;[5] together, ESPS
II and ESPRIT show that the combination of aspirin and
dipyridamole is superior to aspirin alone in preventing recurrent
stroke and other vascular events [4,5] thereby making it unethical
to continue randomising patients to aspirin mono-therapy. As a
result, many of the analyses are very underpowered such as the
neutral findings for effects of dipyridamole on haemodynamic
measures, these probably reflecting a type II error. A further
important criticism is that the recruited patients were at low risk of
recurrence; specifically, they were younger than most patients
presenting with stroke (mean age 62 years) and were enrolled up to 5
years after the index event (median 12 months) whereas the risk of
recurrence is highest in the first few hours and days after ictus.
Furthermore, the majority of patients presented with a lacunar
stroke, again a group at relatively low risk of recurrence. Hence, the
balance between risk of recurrence (low) and bleeding (relatively high
on triple therapy) was probably inappropriate, a problem also seen in
MATCH and CHARISMA.[9,22] Future trials of triple antiplatelet
therapy should focus on high risk patients with recent events or who
have experienced a further event on dual antiplatelet treatment (so-
called ‘failure’); such studies might limit the length of treatment to
Table 4. Haemodynamic measures; mean (standard deviation); comparison by repeated measures ANOVA (baseline, 2 weeks, 3
months, final follow up).
2 weeks 3 months Final follow up P value
Aspirin (7) Triple (9) Aspirin (8) Triple (9) Aspirin (8) Triple (8)
Systolic BP (mmHg) 129 (21) 146 (17) 131 (15) 140 (16) 147 (21) 139 (16) 0.42
Diastolic BP (mmHg) 73 (10) 77 (13) 80 (13) 77 (13) 79 (10) 79 (9) 0.79
Pulse pressure (mmHg) 56 (15) 68 (17) 52 (13) 63 (16) 68 (12) 61 (18) 0.39
Postural drop systolic BP (mmHg){ 2 (15) 212 (7) 24 (18) 211 (11) 213 (15) 21 (24) 0.37
Heart rate (bpm) 71 (12) 82 (15) 72 (11) 74 (12) 76 (10) 72 (13) 0.55
Rate-pressure product (mmHg.bpm) 9105 (1959) 11948 (2565) 9399 (1393) 10421 (1962) 11085 (1823) 9919 (1915) 0.19
{Measured as standing systolic-sitting systolic.
doi:10.1371/journal.pone.0002852.t004
Figure 2. Frequencies of adverse events in aspirin and triple therapy groups.
doi:10.1371/journal.pone.0002852.g002
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cover the period of maximum risk of recurrence, e.g. for the first
three months after ictus.
Generalizability
Analogous trials of triple antiplatelet therapy have been done in
other groups of patients at high risk of vascular events. These were
analysed in a recent systematic review comparing 23 completed
randomised controlled trials assessing various classes of antiplatelet
therapy; in comparison with aspirin-based dual or mono therapy,
triple therapy significantly reduced vascular events, myocardial
infarction and death (in high risk vascular syndromes) offset with
an increased bleeding risk. [Geeganage, Wilcox, Bath, unpub-
lished data] There was, however, insufficient data on ischaemic
stroke highlighting the need for further research in this area.
Overall evidence
Despite the above limitations, this study is the first long-term
randomised controlled trial of combined aspirin, clopidogrel and
dipyridamole after stroke and provides valuable safety and
feasibility data, and guidance on how future trials should be
performed. Further evidence is now required regarding the safety
and efficacy of triple therapy for the secondary prevention of
stroke in patients at high risk of recurrence. This approach may be
useful in those patients who have a recurrent stroke on dual
therapy.[17] In light of ESPS 2 and ESPRIT [4,5] confirming the
superiority of aspirin and dipyridamole versus aspirin alone, future
trials will need to compare the effect of adding clopidogrel to dual
therapy versus dual therapy alone.
Supporting Information
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DOC)
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